Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allopurinol and Trimetazidine as a Preventive of Contrast-associated Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention

NCT05540184 is registered in ClinicalTrials.gov with Beni-Suef University as lead sponsor.

NCT NCT05540184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05540184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allopurinol and Trimetazidine as a Preventive of Contrast-associated Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention
Lead sponsor
Beni-Suef University
Phase
Phase 4
Overall status
Unknown status
Start date
September 19, 2022
Completion date
September 30, 2025
Enrollment
124 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aki - acute kidney injury